Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
|
Your cart is empty |
|||
Showing 1 - 4 of 4 matches in All Departments
Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.
Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.
Is the increased susceptibility of blacks to kidney failure from HIV-AIDS explained by biology or socioeconomic variables? Is kidney failure an early or late complication of HIV infection? Are there receptors for HIV in kidney tissue and is the kidney a major reservoir for the virus? Is acute renal failure an inevitable consequence of drug treatment in HIV disease? Should kidney or solid organ transplantation be offered to patients with HIV infection? Can HIV-associated nephrotherapy be prevented or reversed by drug therapy and has HAART eradicated pediatric HIV nephrotherapy? What is the level of risk to staff and other patients in dialysis facilities that treat HIV-infected patients? These questions and other critical issues are addressed in-depth by some of the world's leading basic scientists and clinician researchers in kidney disorders of HIV-AIDS.
|
You may like...
Eight Days In July - Inside The Zuma…
Qaanitah Hunter, Kaveel Singh, …
Paperback
(1)
1 Recce: Volume 3 - Through Stealth Our…
Alexander Strachan
Paperback
Herontdek Jou Selfvertroue - Sewe Stappe…
Rolene Strauss
Paperback
(1)
Birds Of Greater Southern Africa
Keith Barnes, Terry Stevenson, …
Paperback
(4)
Heart Of A Strong Woman - From Daveyton…
Xoliswa Nduneni-Ngema, Fred Khumalo
Paperback
|